EQS-Adhoc: Termination of the botulinum toxin project
|
EQS-Ad-hoc: HAEMATO AG / Key word(s): Strategic Company Decision
Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out. After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the project for a proprietary botulinum toxin. This decision has no impact on the company's operating business.
About HAEMATO: HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de. Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.ag End of Inside Information
15-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | HAEMATO AG |
| Lilienthalstraße 5c | |
| 12529 Schönefeld | |
| Germany | |
| Phone: | +49 (0)30 897 30 86 70 |
| Fax: | +49 (0)30 897 30 86 79 |
| E-mail: | ir@haemato.ag |
| Internet: | www.haemato.ag |
| ISIN: | DE000A289VV1 |
| WKN: | A289VV |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1774581 |
| End of Announcement | EQS News Service |
|
|
1774581 15-Nov-2023 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 274,12 | 197,84 | 238,33 | 285,04 | 248,14 | 281,51 | 278,00 | |
| EBITDA1,2 | 9,96 | 1,90 | 3,31 | 12,64 | 9,66 | 11,50 | 11,10 | |
| EBITDA-Margin3 | 3,63 | 0,96 | 1,39 | 4,43 | 3,89 | 4,09 | 3,99 | |
| EBIT1,4 | 8,50 | -18,68 | 1,63 | 11,16 | 8,30 | 10,57 | 10,30 | |
| EBIT-Margin5 | 3,10 | -9,44 | 0,68 | 3,92 | 3,35 | 3,76 | 3,71 | |
| Net Profit (Loss)1 | 6,28 | -1,17 | -4,83 | 6,53 | 8,19 | 7,74 | 7,30 | |
| Net-Margin6 | 2,29 | -0,59 | -2,03 | 2,29 | 3,30 | 2,75 | 2,63 | |
| Cashflow1,7 | 0,56 | -2,76 | 14,67 | 14,05 | 19,73 | -3,32 | 8,40 | |
| Earnings per share8 | 2,70 | -0,50 | -1,02 | 1,35 | 1,57 | 1,48 | 1,40 | |
| Dividend per share8 | 1,00 | 0,00 | 0,00 | 1,10 | 1,20 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Harry Haseloff
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Haemato | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A289VV | DE000A289VV1 | AG | 55,43 Mio € | 05.12.2005 | - | 9F4M9H86+67 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 6,75 | 14,80 | 0,46 | 5,83 | 0,37 | -16,70 | 0,20 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 1,20 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 16.07.2024 | 23.04.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -20,72% | -32,05% | -60,15% | -58,59% | +0,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
